IRRA - PT. Itama Ranoraya Tbk

Rp 2.600

-110 (-4,23%)

JAKARTA - PT Itama Ranoraya Tbk (IRRA) targets 80%-100% performance growth in 2021, continuing various strategies that the company has implemented since 2020. Director of IRRA, Pratoto Satno Raharjo, is optimistic about this growth target.

The first strategy, IRRA, a medical device supplier company, have carried out antigen swab tests since 2020, which reached 2.4 million in Q4 2020. This year, the company is targeting 5 to 10 million tests. "In January alone, [the company] has reached 1.5 million [antigen swab tests]," said Mr Raharjo in an information disclosure on the IDX, Tuesday (12/1/2021).

Second, the company targets to start sales on a new brand, called Avimac, immunomodulators to increase the body's immune system, which, in turn, can support the acceleration of handling Covid-19 in Indonesia. This product has received distribution permit from BPOM (Indonesian Food and Drug Administration) as supplements and has been manufactured in Australia.

Third, the company is currently preparing to shift business model, from medical equipment supplier to medical equipment manufacturer and inventor. "This is to expand IRRA's business innovation space and strengthen positioning, such as cooperation with partner producers," said Mr Raharjo.

Lastly, this year, the company will also fully operate a new factory, through sister company PT OneJect Indonesia, with a total capacity of 1.2 billion single-use syringes and safety needles per year, in order to become the largest syringe supplier in ASEAN, with a target in the global market.

Early indicators estimated IRRA's performance grew in 2020, 90%-95% in revenue and 70%-80% in net profit, compared to 2019 (YoY). (AM/AC)